Local perivascular application of low amounts of a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs

Acta Physiologica Scandinavica

Volumn 176, Issue 2, 2002, Pages 151-159

  Nikol, S ^b   Engelmann, M G ^c   Pelisek, J ^c   Fuchs, A ^c   Golda, A ^c   Shimizu, M ^c   Mekkaoui, C ^a   Rolland, P H ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c NONE

Author keywords

Endothelial factors; Gene therapy; Growth factors; Morphogenesis; Therapeutic angiogenesis; Vascular endothelial growth factor

Indexed keywords

LIPOSOME; VASCULOTROPIN;

ANGIOGENESIS; ANGIOGRAPHY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFECT; DRUG SAFETY; FOLLOW UP; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HEART INFARCTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CORONARY STENOSIS; DNA; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; GENETIC VECTORS; ILIAC ARTERY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMIDS; SWINE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036402094     PISSN: 00016772     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-201X.2002.01018.x     Document Type: Article

References (21)

1. Armeanu, S., Pelisek, J., Krausz, E. et al. 2000. Optimization of liposomal gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol Ther 1, 366-375.
2. Baumgartner, I., Pieczek, A., Manor, O. et al. 1998. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97, 1114-1123.
3. Bauters, C., Asahara, T., Zheng, L.P. et al. 1994. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol 267, H1263-H1271.
4. Carmeliet, P., Lampugnami, M.G., Moons, L. et al. 1999. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-[mediated endothelial survival and angiogenesis. Cell 98, 147-157.
5. Chleboun, J.O., Martins, R.N., Mitchell, C.A. & Chirila, T.V. 1992. bFGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem Biophys Res Commun 185, 510-516.
6. Ferguson, M.W., Whitby, D.J., Shah, M., Armstrong, J., Siebert, J.W. & Longaker, M.T. 1996. Scar formation: the spectral nature of fetal and adult wound repair. Plast Reconstr Surg 97, 854-860.
7. Gale, N.W. & Yancopoulos, G.D. 1999. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13, 1055-1066.
8. Gorge, G., Schmidt, T., Ito, B.R., Pantely, G.A. & Schaper, W. 1989. Microvascular and collateral adaptation in swine hearts following progressive coronary artery stenosis. Basic Res Cardiol 84, 524-535.
9. Groth, D., Keil, O., Schneider, M. & Reszka, R. 1998. Transfection assay for dual determination of toxicity and gene expression. Anal Biochem 258, 141-143.
10. Hashimoto, T., Buxton, D.B., Krivokapich, J., Hansen, H.W., Phelps, M.E. & Schelbert, H.R. 1994. Responses of blood flow, oxygen consumption, and contractile function to inotropic stimulation in stunned canine myocardium. Am Heart J 127, 1250-1262.
11. Huehns, T.Y., Krausz, E., Mrochen, S. et al. 1999. Neointimal growth can be influenced by local adventitial gene manipulation via a needle injection catheter. Atherosclerosis 144, 135-150.
12. Isner, J.M., Pieczek, A., Schainfeld, R. et al. 1996. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370-374.
13. Losordo, D.W., Vale, P.R., Symes, J.F. et al. 1998. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98, 2800-2804.
14. Nikol, S., Huehns, T.Y., Krausz, E. et al. 1999. Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Ther 6, 737-748.
15. Nikol, S., Murakami, N., Pickering, J.G. et al. 1997. Differential expression of nonmuscle myosin II isoforms in human atherosclerotic plaque. Atherosclerosis 130, 71-85.
16. Pelisek, J., Armeanu, S. & Nikol, S. 2001. Quiescence, cell viability, apoptosis and necrosis of smooth muscle cells using different growth inhibitors. Cell Proliferation 34, 305-320.
17. Shi, Y., Pieniek, M., O'Brien, J., Mannion, J.D. & Zalewski, A. 1996. Adventitial remodeling after coronary arterial injury. Circulation 93, 340.
18. Sylven, C., Sarkar, N., Ruck, A. et al. 2001. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron Artery Dis 12, 239-243.
19. Symes, J.F., Losordo, D.W., Vale, P.R. et al. 1999. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68, 830-836.
20. Vale, P.R., Losordo, D.W., Milliken, C.E., Esakof, D.D. & Isner, J.M. 1999. Images in cardiovascular medicine: percutaneous myocardial gene transfer of phVEGF-2. Circulation 100, 2462-2463.
21. Vale, P.R., Losordo, D.W., Milliken, C.E. et al. 2000. Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102, 965-974.